We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 24

Changes at PMPRB to safeguard against excessively priced medicines
  • Gowling Lafleur Henderson LLP
  • Canada
  • February 9 2016

Over the course of the next three years, PMPRB is seeking to change to its operations with the aim of becoming a more effective and stronger consumer


Health Canada seeks comment on revised SEB Guidance Document: New requirements for SEB sponsors
  • Gowling Lafleur Henderson LLP
  • Canada
  • January 20 2016

On Dec. 7, 2015, Health Canada released a revised Guidance Document for sponsors of Subsequent Entry Biologics (SEB). The proposed revisions


PM(NOC) regulation amendments now in force
  • Gowling Lafleur Henderson LLP
  • Canada
  • June 30 2015

Industry Canada has now enacted the amendments to the Patented Medicines (Notice of Compliance) Regulations (Regulations) in order to permit claims


Industry Canada seeks comment on proposed changes to listing requirements under the PM(NOC) Regulations
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 6 2015

On May 2, 2015, the Governor in Council issued proposed amendments to Sections 2, 3, and 4 of the Patented Medicines (Notice of Compliance


Federal Court rejects NIA defence and awards compound interest on patent damages
  • Gowling Lafleur Henderson LLP
  • Canada
  • January 24 2015

On Jan. 23, 2015, the Federal Court released its decision regarding the quantum of damages recoverable by Eli Lilly (“Lilly”) in an action relating


Supreme Court upholds Ontario restrictions on Formulary listing of private label products
  • Gowling Lafleur Henderson LLP
  • Canada
  • November 22 2013

In a 7-0 decision released November 22, 2013, the Supreme Court found that the DIDFA & ODBA regulations are valid and that companies controlled by


Federal court rejects PMPRB Copaxone decision on excessive prices again
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 3 2013

By a decision of Justice Zinn dated April 30, 2013, the Federal Court quashed a Board's decision on excessive pricing of Copaxone - for the second


Utility, sound prediction and promise of the patent
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 22 2013

In recent years, attacks on the lack of sound prediction and failure to meet the promise of the patent have proven to be a crushing hammer in the


Court affirms utility of Gleevec patent
  • Gowling Lafleur Henderson LLP
  • Canada
  • February 20 2013

"Sound prediction's introduction into Canadian law was not, as I understand it, to give a crushing hammer to those who challenge patents." Snider J


Gilead Sciences Canada, Inc. v. Canada (Minister of Health), 2012 FC 2, Complera (tenofovir, emtricitabine and rilpivirine), patent listing decision
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 3 2012

In this case the Court accepted the Minister’s position that a patent with combination patent claims and formulation claims to a triple medicinal ingredient product was not eligible for listing